“…e use of cytokine inhibitors tocilizumab, anakinra, and baricitinib is a potential option for the treatment of severe COVID-19 [33], but none of them have been investigated in prospective clinical trials in the pediatric population. In five reviews among patients with MIS-C, the following therapies were employed: intravenous immunoglobulin (63-100%), corticosteroids (49-70%), anakinra (8-13%), tocilizumab (6.5-27%), remdesivir (3-8%), infliximab (1.2-8%), and plasma (n � 3) [24,26,27,29,[36][37][38]. Intravenous immunoglobulin combined with methylprednisolone compared to intravenous immunoglobulin alone is significantly effective in reducing fever, the need for second-line drug therapy, hemodynamic support, and length of intensive care stay [39].…”